In 1997, a mutation in a single gene was found to cause accelerated ageing in mice — premature organ failure, arterial calcification, muscle atrophy, cognitive decline, all within months. The gene was named after Klotho, the Greek goddess who spins the thread of life. What the gene produces is a hormone-like protein that turns out to be one of the most important regulators of the ageing process we have ever identified.
Klotho is a type-1 transmembrane protein encoded by the KL gene, expressed primarily in the kidneys and brain. It exists in two forms: membrane-bound Klotho, which acts locally in the cells where it is expressed, and soluble Klotho, which is cleaved from the cell surface and circulates in the blood, where it can act systemically across multiple organ systems.
Soluble Klotho functions as a co-receptor for FGF23 (fibroblast growth factor 23), regulating phosphate metabolism and vitamin D activation. But its functions extend far beyond this — it modulates insulin signalling, suppresses oxidative stress, inhibits the Wnt signalling pathway (which drives cellular senescence when overactive), and regulates ion channels involved in cardiac function.
Klotho levels fall significantly with age. Studies measuring serum alpha-Klotho show a roughly 40% reduction between ages 30 and 70 in healthy individuals. Lower Klotho levels are associated with: increased cardiovascular risk, accelerated kidney function decline, reduced bone density, impaired cognitive function, increased inflammatory burden and reduced muscle mass.
The relationship is bidirectional — Klotho deficiency appears to accelerate many of the processes we associate with ageing, while those same ageing processes appear to further suppress Klotho expression. It is one of the clearest examples in longevity research of a feedback loop that, once initiated, compounds over time.
Animal studies with Klotho are among the most striking in longevity science. Klotho-deficient mice age rapidly and die within months. Mice overexpressing Klotho live 20-30% longer than controls — healthy and functional throughout the extended lifespan, not merely surviving longer in a deteriorated state. This is the distinction researchers care about: healthspan, not just lifespan.
Human studies show correlational data consistent with the animal findings. Higher circulating Klotho levels in elderly populations are associated with better cognitive function, lower dementia risk, greater muscle strength and reduced all-cause mortality. A 2023 study in Nature Aging found that a single injection of soluble Klotho improved cognitive function in aged primates — a finding that drew significant attention because it demonstrated that the effect was not just correlational but causal and pharmacologically achievable.
Researchers are currently investigating several approaches to Klotho restoration: recombinant Klotho protein administration, gene therapy to upregulate KL gene expression, and small molecules that increase endogenous Klotho production. None are clinically approved. The research is genuinely active and genuinely promising.
Several interventions have shown evidence of increasing Klotho levels in human studies: aerobic exercise (particularly endurance training), vitamin D supplementation in deficient individuals, reduction of dietary phosphate load, and caloric restriction. These are modest effects compared to what pharmacological restoration might achieve, but they are real and accessible.
For context: a 2019 study found that 6 months of aerobic training increased serum Klotho by approximately 12% in previously sedentary elderly adults. Meaningful, but far from restoring the levels of a 30-year-old.
Klotho is not technically a peptide — it is a protein, which is a larger molecule. But it operates as a signalling molecule in ways that overlap substantially with the peptide mechanisms this platform documents, and the research trajectory is closely related. The reason it matters to anyone following peptide science is that it represents one of the clearest examples of a single molecular decline driving a cascade of ageing effects — and one of the strongest cases that restoring specific molecular signals might genuinely reverse, rather than merely slow, aspects of biological ageing.
This is currently a research compound. Nothing commercially available has demonstrated reliable Klotho restoration in humans at scale. The research is worth watching closely.
Enter your email and we'll notify you when we publish something new. Free. No Pep IQ account required. Unsubscribe anytime.
Complete reference entries, protocol guidance and blood work calendars for the compounds in active use.